Genomics, Immune Response, In-Vitro and Sales

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Genomics

Immune Response

In-Vitro

Sales

What to expect from PEGS Europe 2023: Day 1

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Luncheon presentations will be given by Andrew Bradbury, MB BS, PhD, Chief Scientific Officer, Specifica, and Stefanie Kall, Ph.D.,

Antibody

Antibody Engineer Protein Scientist

Roche’s Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer

The Pharma Data

MAY 4, 2021

Tecentriq significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy in a Phase III study. Tecentriq approval offers an alternative to chemotherapy for all eligible patients. We are delighted to bring Tecentriq to people in the EU with this specific type of lung cancer,” said Levi Garraway, M.D.,

HR Protein In-Vitro Medicine

Clinical Research Informer

What to expect from PEGS Europe 2023: Day 1

Roche’s Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer

Stay Connected